In conclusion, these results demonstrated that higher serum VISTA levels were correlated with the most aggressive tumor subtypes (HER2-positive or triple-negative) and poor clinicopathological features, as the association to the metastization process in luminal A subtype. Here, ERBB2 is linked to neoplasm.